Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Resolution of Thrombi in Left Atrial Appendage With Edoxaban

cases (> 90%). Anticoagulation with a vitamin-K antagonist (VKA) is recommended to prevent thromboembolic complications and to resolve thrombi. Non-VKA oral anticoagulants (NOACs) have replaced the

fibrillation
anticoagulants
noac
stroke
heparin
  • 0 views
  • 25 Jan, 2021
  • 11 locations
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

and insulin) leads to decreased therapeutic efficacy of the blood-thinning vitamin-K antagonist warfarin. Due to the non-specific effect of glucose lowering drugs, the investigators hypothesize that

plasma glucose
metformin
sulfonylurea
body mass index
antidiabetic agents
  • 0 views
  • 29 Jan, 2021
  • 1 location
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.

anticoagulants
thrombosis
vitamin k antagonist
warfarin
deep vein thrombosis
  • 0 views
  • 25 Jan, 2021
  • 7 locations
Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS

To show if a combination therapy of rivaroxaban plus Aspirin is more efficient (superiority testing) as rivaroxaban alone in the prevention of early venous stent thrombosis in patients suffering from post-thrombotic syndrome in the first 6 months following endovascular therapy To demonstrate tolerability of combination therapy of Aspirin plus rivaroxaban …

blood clot
clot
stenosis
rivaroxaban
duplex ultrasound
  • 51 views
  • 24 Jan, 2021
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the treatment of post-STEMI left ventricular thrombus.

clopidogrel
stemi
clot
troponin
angiography
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Nurse-coordinated Integrated Care Model for Patients With Atrial Fibrillation

This study aims to evaluate the effects of a nurse-coordinated, empowerment-based integrated care model on self-care behaviors and psychosocial outcomes in patients with atrial fibrillation (AF), and to explore how this intervention affects the self-care behaviors and quality of life from the patients' perspective. Stroke prevention by oral anticoagulants (OAC) …

vascular disease
anticoagulants
arrhythmia
anticoagulation therapy
stroke
  • 1 views
  • 27 Jan, 2021
  • 1 location
An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

major bleeding in which patients are treated for Vitamin K antagonist reversal, the risk of thromboembolic events (TEE) in patients treated with Kcentra and in patients treated with plasma will be

  • 13 views
  • 24 Jan, 2021
  • 1 location
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020

Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K

  • 0 views
  • 29 Jan, 2021
  • 2 locations
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants

(include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin K antagonist. With lack of predicted biomarkers

  • 7 views
  • 28 Jan, 2021
  • 21 locations
START-Register: Survey on Anticoagulated Patients Register

they start the anticoagulant treatment, whatever the drug used, or when they shift from a vitamin K antagonist (VKA) drug to one of the novel direct oral anticoagulants, provided that the therapy is

vitamin k antagonist
vitamin k
anticoagulants
  • 0 views
  • 23 Jan, 2021